Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors?

Endocrine

Volumn 42, Issue 1, 2012, Pages 3-4

  Öberg, Kjell ^a,b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOTANOC GA 68; DOTATATE GA 68; DOTATATE LU 177; DOTATOC GA 68; DOTATOC Y 90; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR GA 68; UNCLASSIFIED DRUG;

CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; EDITORIAL; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; THORACIC NEUROENDOCRINE TUMOR; TUMOR DIAGNOSIS;

EID: 84864979948     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9681-4     Document Type: Editorial

References (10)

1. D.Y. Lee, K.C. Li, Molecular theranostics: a primer for the imaging professional. AJR Am. J. Roentgenol. 197, 318-324 (2011)
2. J.C. Reubi, B. Waser, Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 30, 781-793 (2003)
3. I.M. Modlin, K. Oberg, D.C. Chung, R.T. Jensen, W.W. de Herder, R.V. Thakker, M. Caplin, G. Delle Fave, G.A. Kaltsas, E.P. Krenning, S.F. Moss, O. Nilsson, G. Rindi, R. Salazar, P. Ruszniewski, A. Sundin, Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9, 61-72 (2008)
4. E.P. Krenning, D.J. Kwekkeboom, W.H. Bakker, W.A. Breeman, P.P. Kooij, H.Y. Oei, M. van Hagen, P.T. Postema, M. de Jong, J.C. Reubi et al., Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe1- and 123I-Tyr3-octreotide: the Rotterdam experience with more than 1,000 patients. Eur. J. Nucl. Med. 20, 716-731 (1993)
5. P. Antunes, M. Ginj, H. Zhang, B. Waser, R.P. Baum, J.C. Reubi, H. Maecke, Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur. J. Nucl. Med. Mol. Imaging 34, 982-993 (2007)
6. R.P. Baum, V. Prasad, Molecular imaging of neuroendocrine tumors using Ga-68 DOTA-NOC receptor PET/CT semiquantitative analyses after 1,257 studies (EPOS). In European Congress of Radiology, Edition Vienna, Austria, (2007)
7. S. Koukouraki, L.G. Strauss, V. Georgoulias, J. Schuhmacher, U. Haberkorn, N. Karkavitsas, A. Dimitrakopoulou-Strauss, Evaluation of the pharmacokinetics of 68 Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90YDOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 33, 460-466 (2006)
8. J. Kowalski, M. Henze, J. Schuhmacher, H.R. Macke, M. Hofmann, U. Haberkorn, Evaluation of positron emission tomography imaging using 68 Ga-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol. Imaging Biol. 5, 42-48 (2003)
9. M. Gabriel, C. Decristoforo, D. Kendler, G. Dobrozemsky, D. Heute, C. Uprimny, P. Kovacs, E. Von Guggenberg, R. Bale, I.J. Virgolini, 68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 48, 508-518 (2007)
10. G. Treglia, P. Castaldi, G. Rindi, A. Giordano, V. Rufini, Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis, Endocrine (2012)